Kyntra Bio (NASDAQ:KYNB) Price Target Cut to $8.00 by Analysts at Lake Street Capital

Kyntra Bio (NASDAQ:KYNB – Get Free Report) had its target price reduced by investment analysts at Lake Street Capital to $8.00 in a report issued on Tuesday, Benzinga reports. The brokerage currently has a “buy” rating on the stock. Lake Street Capital‘s target price indicates a potential upside of 284.62% from the stock’s previous close.

Several other analysts have also issued reports on the stock. HC Wainwright cut their price target on shares of Kyntra Bio to $18.00 and set a “buy” rating for the company in a research report on Tuesday. Zacks Research raised Kyntra Bio from a “strong sell” rating to a “hold” rating in a research note on Tuesday, November 10th. Weiss Ratings downgraded Kyntra Bio from a “sell (d+)” rating to a “sell (d)” rating in a report on Tuesday, November 10th. Finally, Maxim Group initiated coverage on Kyntra Bio in a research note on Tuesday, October 13th. They issued a “buy” rating and a $35.00 target price for the company. Five research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Kyntra Bio presently has an average rating of “Moderate Buy” and an average price target of $25.20.

View Our Latest Research Report on Kyntra Bio

Kyntra Bio Stock Down 35.0%

Shares of NASDAQ KYNB traded down $1.12 during mid-day trading on Tuesday, reaching $2.08. 172,101 shares of the company were exchanged, compared to its average volume of 23,989. Kyntra Bio has a 52 week low of $2.02 and a 52 week high of $10.47. The company’s 50 day moving average price is $5.73 and its 200 day moving average price is $6.84. The stock has a market capitalization of $8.42 million, a PE ratio of 0.04 and a beta of 1.08.

Hedge Funds Weigh In On Kyntra Bio

A hedge fund recently bought a new position in Kyntra Bio stock. Renaissance Technologies LLC bought a new position in shares of Kyntra Bio Inc (NASDAQ:KYNB – Free Report) during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 27,481 shares of the company’s stock, valued at approximately $186,000. Renaissance Technologies LLC owned about 0.68% of Kyntra Bio as of its most recent filing with the Securities and Exchange Commission (SEC). 72.71% of the stock is owned by hedge funds and other institutional investors.

Kyntra Bio Company Profile

(Get Free Report)

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes.

Further Reading

Analyst Recommendations for Kyntra Bio (NASDAQ:KYNB)

Receive News & Ratings for Kyntra Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kyntra Bio and related companies with MarketBeat.com's FREE daily email newsletter.